In the prostate-specific antigen (PSA) era, prostate cancer is detected at more local stages.
Nevertheless, depending on e.g. the differentiation stage there is recurrent disease in 10-40% of the cases with the need of further treatment. Once hormonal therapy has been initiated the disease can progress to the castration resistant stage and the question of chemotherapy arises. At this stage PSA sensitivity decreases. Although there is a significant improvement in survival only about 50% of the patients benefit from chemotherapy. Recently several new drugs have or will soon be approved in the setting of castration-resistant prostate cancer (CRPCA). Several prognostic molecular markers have been investigated. In this review some objective important biomarkers, proteins and targets will be presented.
Written by:
Pfister D, Heidenreich A, Porres D. Are you the author?
Klinik für Urologie, Universitätsklinikum Aachen, Pauwelsstraße 30, 52074, Aachen, Deutschland.
Reference: Urologe A. 2013 Sep;52(9):1261-4.
doi: 10.1007/s00120-013-3318-y
PubMed Abstract
PMID: 23975220
Article in German.
UroToday.com mCRPC Treatment Section
